会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Process for the production of substituted
4-thia-2,6-diaza[3.2.0]-2-heptene-7-one
    • 制备取代的4-硫杂-2,6-二氮杂{8 3.2.0 {9,2-庚烯-7-酮
    • US4155911A
    • 1979-05-22
    • US820895
    • 1977-08-01
    • Maurizio FoglioAntonino SuaratoPaolo MasiGiovanni FranceschiGiorgio PalamidessiLuigi Bernardi
    • Maurizio FoglioAntonino SuaratoPaolo MasiGiovanni FranceschiGiorgio PalamidessiLuigi Bernardi
    • C07D205/08C07D513/04
    • C07D513/04C07D205/08
    • A new process is disclosed for the preparation of compounds of structure: ##STR1## and are as defined herein characterized in that a compound of structure ##STR2## where R and R.sup.1 have the meanings given herein, is reacted in a suitable solvent with a haloamide in the presence of a metal oxide or a haloamide in the presence of a free radical initiator under the influence of light or heat or alternatively with a halogen in the presence of a metal oxide, to give a compound of structure: ##STR3## where R and R.sup.1 have the meanings given herein, Hal is a halogen atom; THE INTERMEDIATE COMPOUND (III) in a suitable solvent is then reacted with an appropriate nucleophilic reagent to obtain the compound IV where Z replaces Hal, where Z is defined herein;The compound (IV) is then subjected to an allylic halogenation in a suitable solvent by reacting it with a haloamide either under the influence of light alone or by heating it in the presence of a free radical initiator, to give a compound of structure: ##STR4## where R, R.sup.1 and Hal and Z have the above meanings; THE INTERMEDIATE COMPOUND (V) is then reacted with a reducing agent to give finally the desired compound (I).
    • 公开了用于制备结构式(I)的化合物的新方法,其定义如下,其特征在于其中R和R 1具有本文给出的含义的结构式(II)的化合物在 在金属氧化物或卤代酰胺的存在下,在自由基引发剂的存在下,在光或热的作用下,或者在卤素存在下,在金属氧化物的存在下,与卤代酰胺合适的溶剂,得到结构化合物 (III)其中R和R1具有本文给出的含义,Hal是卤素原子; 然后将合适的溶剂中的中间体化合物(III)与合适的亲核试剂反应,得到Z代替Hal的化合物IV,其中Z在本文中定义; 然后使化合物(IV)在合适的溶剂中通过与单独的光的影响下的卤代酰胺反应或通过在自由基引发剂的存在下加热使其与卤代酰胺反应,得到结构式 (V)其中R,R1,Hal和Z具有上述含义; 然后将中间体化合物(V)与还原剂反应,最终得到所需化合物(I)。
    • 7. 发明授权
    • Anthracycline derivatives, their preparation and use
    • 蒽环类衍生物,其制备和用途
    • US4327029A
    • 1982-04-27
    • US2072
    • 1979-01-08
    • Luigi BernardiPaolo MasiAntonino SuaratoFederico Arcamone
    • Luigi BernardiPaolo MasiAntonino SuaratoFederico Arcamone
    • A61K31/65A61K31/70A61K31/7028A61K31/7034A61K31/704A61P35/00C07H15/252C07C39/40
    • C07H15/252Y10S514/908
    • Compounds of the formula: ##STR1## wherein R.sub.1 is a C.sub.2 -C.sub.4 alkyl; a C.sub.3 -C.sub.6 cycloalkyl or benzyl; A and B are OH or A and B are OCOOR.sub.4 or B is OH and A is OCOOR.sub.4 ; and R.sub.4 is alkyl which are intermediates for the preparation of antitumor compounds of the formula: ##STR2## wherein R.sub.1 is a C.sub.2 -C.sub.4 alkyl; a C.sub.3 -C.sub.6 cycloalkyl; a C.sub.3 -C.sub.6 cycloalkyl substituted by a halogen, hydroxy, methoxy, amino or dimethylamino group; phenyl or phenyl substituted with nitro, chlorine or methoxy thiazyl, pyridyl, pyrazyl; or a phenyl-alkyl group of the formula X--Phe--(CH.sub.2).sub.n --, in which X is hydrogen, halogen, hydroxyl, amino, or nitro and n is an integer from 1 to 2; R.sub.2 is hydrogen, hydroxyl or acyloxy (R--COO--); where R is an alkyl having from 1 to 11 carbon atoms; and R.sub.3 is hydrogen or trifluoroacetyl and salts thereof with pharmaceutically acceptable acids.
    • 下式的化合物:其中R 1是C 2 -C 4烷基; C3-C6环烷基或苄基; A和B是OH或A,B是OCOOR4或B是OH,A是OCOOR4; 和R4是作为制备下式的抗肿瘤化合物的中间体的烷基:其中R 1是C 2 -C 4烷基; C3-C6环烷基; 被卤素,羟基,甲氧基,氨基或二甲氨基取代的C3-C6环烷基; 苯基或被硝基,氯或甲氧基噻唑取代的苯基,吡啶基,吡嗪基; 或式X-Phe-(CH2)n-的苯基 - 烷基,其中X是氢,卤素,羟基,氨基或硝基,n是1至2的整数; R2是氢,羟基或酰氧基(R-COO-); 其中R是具有1至11个碳原子的烷基; 并且R 3是氢或三氟乙酰基及其盐与药学上可接受的酸。
    • 9. 发明授权
    • Anthracycline derivatives, their preparation and use
    • 蒽环类衍生物,其制备和用途
    • US4166848A
    • 1979-09-04
    • US850933
    • 1977-11-14
    • Luigi BernardiPaolo MasiAntonino SuaratoFederico Arcamone
    • Luigi BernardiPaolo MasiAntonino SuaratoFederico Arcamone
    • A61K31/65A61K31/70A61K31/7028A61K31/7034A61K31/704A61P35/00C07H15/252C07G3/00C07G11/00
    • C07H15/252Y10S514/908
    • Disclosed are antitumor compounds of the formula: ##STR1## wherein R.sub.1 is a C.sub.2 -C.sub.4 alkyl; a C.sub.3 -C.sub.6 cycloalkyl; a C.sub.3 -C.sub.6 cycloalkyl substituted by a halogen, hydroxy, methoxy, amino or dimethylamino group; phenyl or phenyl substituted with nitro, chlorine or methoxy; thiazyl, pyridyl, pyrazyl; or a phenyl-alkyl group of the formula X--Phe--(CH.sub.2).sub.n --, in which X is hydrogen, halogen, hydroxyl, amino, or nitro and n is an integer from 1 to 2; R.sub.2 is hydrogen, hydroxyl or acyloxy (R--COO--), where R is an alkyl having from 1 to 11 carbon atoms; and R.sub.3 is hydrogen or trifluoroacetyl and salts thereof with pharmaceutically acceptable acids. Compounds I are prepared by condensing the aglycones thereof with 2,3,6-trideoxy-3-trifluoroacetamido-4-O-trifluoro-acetyl-.alpha.-L-lyxopyranosyl chloride according to a conventional technique.
    • 公开了下式的抗肿瘤化合物:其中R 1是C 2 -C 4烷基; C3-C6环烷基; 被卤素,羟基,甲氧基,氨基或二甲氨基取代的C3-C6环烷基; 苯基或被硝基,氯或甲氧基取代的苯基; 噻嗪基,吡啶基,吡嗪基; 或式X-Phe-(CH2)n-的苯基 - 烷基,其中X是氢,卤素,羟基,氨基或硝基,n是1至2的整数; R2是氢,羟基或酰氧基(R-COO-),其中R是具有1至11个碳原子的烷基; 并且R 3是氢或三氟乙酰基及其盐与药学上可接受的酸。 通过根据常规技术将其糖苷配基与2,3,6-三脱氧-3-三氟乙酰氨基-4-O-三氟乙酰基-β-L-吡喃葡糖酰氯缩合制备化合物I.